MARATTO

review · Frontiers in Immunology

Clinical and immunological spectra of human cutaneous leishmaniasis in North Africa and French Guiana

202315 citationsOpen accessUniversity of Tunis El Manar

Abstract

Cutaneous leishmaniasis (CL) caused by infection with the parasite Leishmania exhibits a large spectrum of clinical manifestations ranging from single healing to severe chronic lesions with the manifestation of resistance or not to treatment. Depending on the specie and multiple environmental parameters, the evolution of lesions is determined by a complex interaction between parasite factors and the early immune responses triggered, including innate and adaptive mechanisms. Moreover, lesion resolution requires parasite control as well as modulation of the pathologic local inflammation responses and the initiation of wound healing responses. Here, we have summarized recent advances in understanding the in situ immune response to cutaneous leishmaniasis: i ) in North Africa caused by Leishmania (L.) major , L. tropica , and L. infantum , which caused in most cases localized autoresolutives forms, and ii ) in French Guiana resulting from L. guyanensis and L. braziliensis , two of the most prevalent strains that may induce potentially mucosal forms of the disease. This review will allow a better understanding of local immune parameters, including cellular and cytokines release in the lesion, that controls infection and/or protect against the pathogenesis in new world compared to old world CL.

Research topics

  • Research on Leishmaniasis Studies
  • Trypanosoma species research and implications

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3389/fimmu.2023.1134020

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.